PROCEPT BioRobotics (PRCT) vs SI-BONE (SIBN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
SI-BONE (SIBN) has outperformed PROCEPT BioRobotics (PRCT) over the past year, gaining 21.7% versus a loss of 17.3%. Over five years, SIBN leads with a +18.5% price change compared with -30.6% for PRCT. PROCEPT BioRobotics is the larger company by market cap ($1.42 billion vs $1.07 billion), about 1.3 times the size.
SI-BONE converts more of its revenue into profit, with a net margin of -9.4% versus -31.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRCT | SIBN |
|---|---|---|
| Share price | $24.70 | $23.73 |
| Market cap | $1.42B | $1.07B |
| 1-day change | -4.08% | -0.08% |
| YTD return | -21.49% | +20.33% |
| 1-year return | -17.28% | +21.69% |
| 5-year return | -30.64% | +18.53% |
| EPS (TTM) | $-2.02 | $-0.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $308.05M | $200.93M |
| Revenue growth (YoY) | +37.22% | +20.19% |
| Net income (latest FY) | $-95.57M | $-18.90M |
| Gross margin | 63.70% | 79.57% |
| Operating margin | -33.71% | -11.11% |
| Net margin | -31.02% | -9.41% |
| 52-week high | $38.11 | $25.92 |
| 52-week low | $16.67 | $11.48 |
| Distance from 52-week high | -35.19% | -8.45% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | -7.89% | +12.85% |
| Average volume | 1.31M | 709.79K |
| Shares outstanding | 57.54M | 45.11M |
| Employees | 888 | 376 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SIBN has outperformed PRCT by 39.0 percentage points over the past year.
- SI-BONE is more profitable, keeping -9.4 cents of every revenue dollar as net income versus -31.0 cents for PROCEPT BioRobotics.
- PROCEPT BioRobotics grew revenue faster in its latest fiscal year (+37.22% vs +20.19%).
About PROCEPT BioRobotics
PRCT stock →PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia.
Health Care · Medical/Dental Instruments · 888 employees
About SI-BONE
SIBN stock →SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products.
Health Care · Medical/Dental Instruments · 376 employees
PRCT vs SIBN FAQ
Which is bigger, PROCEPT BioRobotics or SI-BONE?
PROCEPT BioRobotics (PRCT) is larger, with a market capitalization of $1.42B compared with $1.07B for SI-BONE (SIBN).
Which stock has performed better over the past year, PRCT or SIBN?
SIBN returned +21.69% over the past 12 months, compared with -17.28% for PRCT (price return, excluding dividends). Past performance does not predict future results.
Are PROCEPT BioRobotics and SI-BONE in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.